Daewoong Pharma대웅제약
069620 · KOSPI · ₩069620 · 대웅제약
₩101,500▲ ₩1,600 (1.60%)End-of-day · Oct 29, 2026 · End-of-day prices.
Filings
- Results of Extraordinary Shareholders' Meeting임시주주총회결과Sep 9, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Sep 9, 2026Open on DART
- Decision on Guarantee of Debt for Another Party타인에대한채무보증결정Sep 4, 2026Open on DART
- Lawsuit filed or ruled소송등의제기ㆍ신청(일정금액이상의청구)Sep 2, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Aug 25, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Aug 25, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 21, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Preliminary earnings영업(잠정)실적(공정공시)Jul 29, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Jul 28, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Jul 28, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법))Jul 10, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 7, 2026Open on DART
- [Corrected] New Facility Investment, etc.[기재정정]신규시설투자등Jun 30, 2026Open on DART
- Disclosure Related to Sustainability Management Report, etc. (Voluntary Disclosure)지속가능경영보고서등관련사항(자율공시)Jun 30, 2026Open on DART
- Major sales or supply contract단일판매ㆍ공급계약체결Jun 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 3상 임상시험계획(IND) 승인(위궤양의 치료 요법))Jun 23, 2026Open on DART
- Disclosure of Corporate Governance Report기업지배구조보고서공시Jun 1, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (엔블로젬(Envlozem)의 국내 품목허가 신청)May 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인)May 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결)May 21, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)May 20, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (INV008(15PGDH 저해제) 기술도입 계약 체결)May 12, 2026Open on DART
- Preliminary earnings영업(잠정)실적(공정공시)May 12, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)May 7, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 국내 품목허가 승인(헬리코박터파일로리 제균을 위한 항생제 병용요법))Apr 30, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Apr 10, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 27, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Mar 27, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Mar 26, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Mar 25, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 18, 2026Open on DART
- Fair Trade Self-Compliance Program Operation Status (Informational Disclosure)공정거래자율준수프로그램운영현황(안내공시)Mar 16, 2026Open on DART
- Audit report submitted감사보고서제출Mar 9, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Mar 5, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Feb 26, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Feb 26, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 25, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Feb 25, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 13, 2026Open on DART
- Sales or supply contract terminated단일판매ㆍ공급계약해지Feb 12, 2026Open on DART
- Preliminary earnings영업(잠정)실적(공정공시)Feb 9, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경Feb 9, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 26, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Jan 23, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 5, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항Dec 19, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 15, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Daewoong Pharma / 대웅제약 / 069620 / KRX:069620
Source: KRX statistical information